BioPharma Credit Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	123.12	122.18	108.45	182.31	84.96	89.14
Loss (Gain) From Sale of Assets	-	-	-	-	-	-9.46
Loss (Gain) From Sale of Investments	-11.37	0.09	23.95	-5.95	23.75	-
Other Operating Activities	-0.02	0	0.01	0.03	0.02	-21.76
Change in Accounts Receivable	-17.67	-11.48	-0.48	-9.83	-9.8	16
Change in Accounts Payable	3.96	1.12	-8.74	17.71	-2.49	-15.84
Operating Cash Flow	98.03	111.91	123.18	184.28	96.44	58.07
Operating Cash Flow Growth	-30.19%	-9.15%	-33.15%	91.09%	66.06%	-55.84%
Investment in Securities	70	39.07	-1.66	48.19	-94.82	-47.47
Investing Cash Flow	70	39.07	-1.66	48.19	-94.82	-47.47
Repurchase of Common Stock	-80.31	-105.75	-17.22	-50.09	-	-0.06
Common Dividends Paid	-56.65	-109.02	-68.95	-95.74	-96.17	-96.17
Financing Cash Flow	-200.89	-280.42	-106.99	-206.62	-100.16	-113.96
Foreign Exchange Rate Adjustments	0.02	-0	-0.01	-0.03	-0.02	-0.01
Net Cash Flow	-32.84	-129.43	14.53	25.82	-98.56	-103.37
Levered Free Cash Flow	63.32	66.9	56.88	124.09	40.26	56.6
Unlevered Free Cash Flow	63.32	66.9	56.88	124.09	40.26	56.6
Change in Working Capital	-13.71	-10.36	-9.22	7.88	-12.29	0.16

Source: S&P Global Market Intelligence. Standard template. Financial Sources.